Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash from Operations: 2009-2025

Historic Cash from Operations for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $5.3 million.

  • Lifecore Biomedical's Cash from Operations fell 38.65% to $5.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$206,000, marking a year-over-year decrease of 180.16%. This contributed to the annual value of -$206,000 for FY2025, which is 180.16% down from last year.
  • Lifecore Biomedical's Cash from Operations amounted to $5.3 million in Q2 2025, which was up 345.58% from $1.2 million recorded in Q1 2025.
  • Lifecore Biomedical's Cash from Operations' 5-year high stood at $8.7 million during Q2 2024, with a 5-year trough of -$17.3 million in Q1 2022.
  • Moreover, its 3-year median value for Cash from Operations was -$1.0 million (2024), whereas its average is -$1.4 million.
  • As far as peak fluctuations go, Lifecore Biomedical's Cash from Operations slumped by 656.49% in 2023, and later surged by 485.32% in 2024.
  • Over the past 5 years, Lifecore Biomedical's Cash from Operations (Quarterly) stood at -$4.8 million in 2021, then soared by 51.08% to -$2.4 million in 2022, then spiked by 154.74% to $1.3 million in 2023, then slumped by 576.71% to -$6.1 million in 2024, then tumbled by 38.65% to $5.3 million in 2025.
  • Its Cash from Operations stands at $5.3 million for Q2 2025, versus $1.2 million for Q1 2025 and -$6.1 million for Q4 2024.